Survodutide — Drug Intelligence | 5 EU Trials

Filter these 5 trials by condition, phase, country and more.

5 Registered trials

1 Recruiting

3 Completed trials

3 Sponsors

18 Countries

Phase III

Phase II

Phase III: 4 Phase II: 1

Oversight events:

2 serious breaches across 2 trials

Indications tested

5 total

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Phase II 3 countries Universitair Medisch Centrum Groningen
A study to test whether survodutide helps people living with obesity or overweight and with a confirmed or presumed liver disease called non… Recruiting

2023-505303-23-00 Phase III 3 countries Boehringer Ingelheim International GmbH
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Phase III 17 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Phase III 6 countries Boehringer Ingelheim International GmbH; Boehringer Ingelheim RCV GmbH & Co. KG
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Phase III 11 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…

Showing 1–5 of 5 trials